Akari Therapeutics announced that its AKTX-101 antibody drug conjugate (ADC), which uses a novel RNA splicing modulator payload, has been accepted for presentation at the ASCO Annual Meeting 2026. This marks a significant milestone as AKTX-101 targets KRAS-mutated tumors, a challenging cancer type, and is set to enter Phase 1 clinical trials by late 2026 or early 2027. The ADC's unique mechanism disrupts RNA splicing in cancer cells, showing strong preclinical results and potential synergy with other cancer therapies. This development highlights Akari's innovative approach to treating difficult cancers and expanding treatment options.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
